| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 23.05.
| CSL Daily share buy-back notice | | 1 | wotnews |
| 21.05.
| Allied Healthcare Group adds former CSL executive's expertise to board | | 1 | Proactive Investors |
| 16.05.
| CSL Daily share buy-back notice | | 1 | wotnews |
| 07.05.
| CSL Daily share buy-back notice | | 3 | wotnews |
| 04.05.
| CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care | | 35 | PR Newswire |
| CHICAGO, May 4, 2012 /PRNewswire/ --Data presented today by CSL Behring at the 2012 Thrombosis and Hemostasis Summit of North America (THSNA) showed that a balanced, human 4-factor prothrombin complex...
Mehr lesen zu:
CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care | |
| 04.05.
| CSL Behring begins Phase I/II hereditary angioedema study | | 2 | Pharma Bus Review |
| 04.05.
| CSL New issue announcement | | 2 | wotnews |
| 03.05.
| CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema | | 40 | PR Newswire |
| KING OF PRUSSIA, Pa. and MARBURG, Germany, May 3, 2012 /PRNewswire/ --CSL Behring announced today that it has initiated an international phase I/II study of a volume-reduced, subcutaneous formulation...
Mehr lesen zu:
CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema | |
| 30.04.
| CSL Daily share buy-back notice | | 2 | wotnews |
| 27.04.
| CSL CORRECTED VERSION New issue announcement 26Apr12 | | 2 | wotnews |
| 26.04.
| CSL New issue announcement | | 3 | wotnews |
| 26.04.
| CSL CORRECTED VERSION Daily share buy-back notice | | 1 | wotnews |
| 19.04.
| Xencor Receives Milestone Payment from CSL Limited Under Antibody Optimization Collaboration | | 21 | PR Newswire |
| MONROVIA, Calif., April 19, 2012 /PRNewswire/ --Xencor, Inc. announced today that the Company received a milestone payment under an antibody optimization collaboration agreement with CSL Limited....
Mehr lesen zu:
Xencor Receives Milestone Payment from CSL Limited Under Antibody Optimization Collaboration | |
| 18.04.
| CSL Daily share buy-back notice | | 3 | wotnews |
| 16.04.
| CSL Behring Renews Pledge to Provide Significant Funding and Donated Coagulation Factor to World Federation of Hemophilia Over 3-Year Period | | 43 | PR Newswire |
| KING OF PRUSSIA, Pa. and MONTREAL, April 16, 2012 /PRNewswire/ -- To mark World Hemophilia Day 2012, CSL Behring has again committed to making significant financial contributions and donations of...
Mehr lesen zu:
CSL Behring Renews Pledge to Provide Significant Funding and Donated Coagulation Factor to World Federation of Hemophilia Over 3-Year Period | |
| 13.04.
| CSL Company Reports - Half Yearly | | 6 | wotnews |
| 11.04.
| CSL Daily share buy-back notice | | 4 | wotnews |
| 03.04.
| CSL New issue announcement | | 7 | wotnews |
| 03.04.
| CSL Daily share buy-back notice | | 3 | wotnews |
| 30.03.
| CSL Behring Commences Phase I Study With rVIIa-FP, a Novel Therapy to Treat People With Hemophilia A and Hemophilia B Who Have Inhibitors | | 45 | PR Newswire |
| KING OF PRUSSIA, Pa., March 30, 2012 /PRNewswire/ -- CSL Behring announced today the first in human dosing of recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). The...
Mehr lesen zu:
CSL Behring Commences Phase I Study With rVIIa-FP, a Novel Therapy to Treat People With Hemophilia A and Hemophilia B Who Have Inhibitors | |
